In BC patients, a high MYBL2 proto-oncogene level may also be a biomarker of adverse prognosis (33, 34) and could promote tumor invasion by the induction of epithelial–mesenchymal transition (EMT) and modulation of immune microenvironment (35, 36). Here, MYBL2 is linked to breast cancer.